We maintain our Neutral recommendation on BioScrip Inc. (NASDAQ:BIOS) with a target price of $5.50.
BioScrip reported EPS of 1 cent in the third quarter of fiscal 2011, down 75% year over year. However, after deducting the impact of restructuring charges, severance and other employee costs, adjusted EPS came in at 10 cents during the quarter, beating the Zacks Consensus Estimate by a penny.
After delivering a few disappointing quarters, impacted by pricing concessions on various specialty drugs, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards